[go: up one dir, main page]

BRPI0407149A8 - formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais - Google Patents

formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Info

Publication number
BRPI0407149A8
BRPI0407149A8 BRPI0407149A BRPI0407149A BRPI0407149A8 BR PI0407149 A8 BRPI0407149 A8 BR PI0407149A8 BR PI0407149 A BRPI0407149 A BR PI0407149A BR PI0407149 A BRPI0407149 A BR PI0407149A BR PI0407149 A8 BRPI0407149 A8 BR PI0407149A8
Authority
BR
Brazil
Prior art keywords
rifaximin
production
polymorphic forms
processes
medicinal preparations
Prior art date
Application number
BRPI0407149A
Other languages
English (en)
Inventor
Braga Dario
Confortini Donatella
C Viscomi Giuseppe
Rosini Goffredo
Campana Manuela
Righi Paolo
Cannata Vincenzo
Original Assignee
Alfa Wassermann Spa
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407149(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa, Alfasigma Spa filed Critical Alfa Wassermann Spa
Publication of BRPI0407149A publication Critical patent/BRPI0407149A/pt
Publication of BRPI0407149A8 publication Critical patent/BRPI0407149A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

"formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais". a presente invenção refere-se a formas polimórficas cristalinas de rifaximin (inn), referidas como rifaximin alfa e rifaximin beta, e a uma forma pobremente cristalina referida como rifaximin gama, úteis na produção de medicamentos contendo rifaximin para o uso oral e tópico e obtidas por meio de um processo de cristalização realizado por dissolução quente de rifaximin bruto em álcool etílico e causando a cristalização do produto pela adição de água em uma temperatura fixada e por um período de tempo fixado, seguido por secagem sob condições controladas até atingir um preciso teor de água no produto final, são os objetos da invenção.
BRPI0407149A 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais BRPI0407149A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
PCT/EP2004/012490 WO2005044823A2 (en) 2003-11-07 2004-11-04 Polymorphous forms of rifaximin as antibiotics

Publications (2)

Publication Number Publication Date
BRPI0407149A BRPI0407149A (pt) 2006-02-07
BRPI0407149A8 true BRPI0407149A8 (pt) 2019-01-15

Family

ID=33187382

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0402382-0A BRPI0402382A (pt) 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais
BRPI0407149A BRPI0407149A8 (pt) 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0402382-0A BRPI0402382A (pt) 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais

Country Status (37)

Country Link
US (5) US7045620B2 (pt)
EP (6) EP1676847B1 (pt)
JP (5) JP2005139161A (pt)
KR (4) KR20050043589A (pt)
CN (4) CN1613858A (pt)
AR (3) AR043547A1 (pt)
AT (3) ATE361927T1 (pt)
AU (2) AU2004200964A1 (pt)
BR (2) BRPI0402382A (pt)
CA (2) CA2460384A1 (pt)
CL (1) CL2004000498A1 (pt)
CO (1) CO5560083A1 (pt)
CY (3) CY1108017T1 (pt)
DE (4) DE602004019296D1 (pt)
DK (3) DK1676847T3 (pt)
ES (3) ES2320160T4 (pt)
HR (2) HRP20040265A2 (pt)
IL (2) IL160798A0 (pt)
IT (1) ITMI20032144A1 (pt)
JO (1) JO2470B1 (pt)
MA (1) MA27069A1 (pt)
MD (1) MD3653G8 (pt)
ME (1) ME00424B (pt)
MX (2) MXPA04002353A (pt)
NO (1) NO334950B1 (pt)
NZ (1) NZ531622A (pt)
PL (3) PL1676848T3 (pt)
PT (3) PT1676848E (pt)
RS (4) RS54568B1 (pt)
RU (1) RU2270200C2 (pt)
SI (3) SI1676848T1 (pt)
TN (2) TNSN04044A1 (pt)
TW (1) TWI285107B (pt)
UA (1) UA86384C2 (pt)
WO (1) WO2005044823A2 (pt)
YU (1) YU24804A (pt)
ZA (1) ZA200401948B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
EP1698630B1 (en) * 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
HUE025306T2 (hu) 2006-08-02 2016-01-28 Salix Pharmaceuticals Inc Sugárterápia által okozott bélgyulladás kezelésére irányuló módszer
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
CA2663776C (en) * 2006-09-22 2016-01-26 Cipla Limited Rifaximin in an amorphous form
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
ES2798253T3 (es) * 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
KR101674382B1 (ko) 2008-02-25 2016-11-09 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
KR20100122937A (ko) * 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
DK2294012T3 (da) 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
RU2011116400A (ru) 2008-09-26 2012-11-10 Аска Фармасьютикал Ко., Лтд. (Jp) Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
HRP20240317T1 (hr) * 2008-10-02 2024-06-07 Salix Pharmaceuticals, Ltd. Liječenje hepatičke encefalopatije uporabom rifaksimina
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
KR20170036116A (ko) * 2009-06-02 2017-03-31 샐릭스 파마슈티컬스 리미티드 간성 뇌병증의 치료방법
WO2011032085A1 (en) 2009-09-13 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
KR102456997B1 (ko) * 2009-10-27 2022-10-19 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
KR20120117788A (ko) 2009-11-23 2012-10-24 시플라 리미티드 국소용 폼 조성물
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ，リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EA022490B1 (ru) * 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SG10201505484RA (en) 2010-07-12 2015-09-29 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
KR20140026379A (ko) 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
US20160047819A1 (en) 2013-03-15 2016-02-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
AU2014229467A1 (en) 2013-03-15 2015-08-06 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
NZ713440A (en) 2013-04-12 2019-02-22 Alfasigma Spa Nsaid administration and related compositions, methods and systems.
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
EP3160467B1 (en) * 2014-06-30 2021-03-10 Salix Pharmaceuticals, Inc. Combination comprising rifaximin and cyclosporine for use in the treatment of bowel diseases
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
ES2893869T3 (es) 2016-03-24 2022-02-10 Sandoz Ag Composición farmacéutica que contiene rifaximina alfa y delta
EP3373914B2 (en) 2016-03-24 2022-06-01 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
EP3416627B9 (en) 2017-04-26 2020-04-22 Sandoz AG Oral dosage form comprising rifaximin in form beta
HUE054832T2 (hu) 2017-06-26 2021-10-28 Biofer Spa Pirido-imidazo rifamicinszármazékok baktériumellenes szerként
EP3902528A1 (en) * 2018-12-19 2021-11-03 Friulchem SpA Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021058656A1 (en) 2019-09-24 2021-04-01 Bausch Health Ireland Limited Rifaximin liquid formulations
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
EP4171520A1 (en) 2020-06-26 2023-05-03 Bausch Health Ireland Limited Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ES2075454T3 (es) * 1990-06-29 1995-10-01 Lepetit Spa Forma cristalina pura de rifapentina.
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
PL361912A1 (en) * 2000-10-31 2004-10-04 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
CA2663776C (en) * 2006-09-22 2016-01-26 Cipla Limited Rifaximin in an amorphous form
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
KR101674382B1 (ko) 2008-02-25 2016-11-09 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도

Also Published As

Publication number Publication date
PT1676848E (pt) 2009-04-09
KR20050043589A (ko) 2005-05-11
AR081992A2 (es) 2012-10-31
AR043547A1 (es) 2005-08-03
HK1092151A1 (en) 2007-02-02
SI1676848T1 (sl) 2009-06-30
US20050101598A1 (en) 2005-05-12
ES2320161T3 (es) 2009-05-19
ES2320160T4 (es) 2011-03-09
RU2270200C2 (ru) 2006-02-20
US20110160449A1 (en) 2011-06-30
RS54569B1 (en) 2016-06-30
CN101260115A (zh) 2008-09-10
HRP20060093B1 (hr) 2015-12-18
EP1557421B1 (en) 2007-05-09
ZA200401948B (en) 2004-04-29
CA2460384A1 (en) 2005-05-07
AU2004200964A1 (en) 2005-05-26
HRP20060093A2 (en) 2006-05-31
MXPA06002644A (es) 2006-06-06
EP1682556A2 (en) 2006-07-26
BRPI0402382A (pt) 2005-06-28
TNSN06069A1 (en) 2007-10-03
MD3653G8 (ro) 2016-08-31
PL1557421T3 (pl) 2007-08-31
KR20060110737A (ko) 2006-10-25
CA2538546A1 (en) 2005-05-19
SI1557421T1 (sl) 2007-08-31
NO20061110L (no) 2006-04-19
MA27069A1 (fr) 2004-12-20
CN1613858A (zh) 2005-05-11
AU2004287601A1 (en) 2005-05-19
KR20070113326A (ko) 2007-11-28
EP2210893A1 (en) 2010-07-28
RU2004108953A (ru) 2005-10-27
JP2011046738A (ja) 2011-03-10
PL1676847T3 (pl) 2009-07-31
DE04005541T1 (de) 2005-12-29
UA86384C2 (uk) 2009-04-27
DE602004019298D1 (de) 2009-03-19
DE602004019296D1 (de) 2009-03-19
US8173801B2 (en) 2012-05-08
NZ531622A (en) 2004-10-29
JP5635376B2 (ja) 2014-12-03
KR100867751B1 (ko) 2008-11-10
JO2470B1 (en) 2009-01-20
NO334950B1 (no) 2014-08-04
RS54571B1 (en) 2016-06-30
DK1676848T3 (da) 2009-05-11
CN1886408A (zh) 2006-12-27
DE602004006367D1 (de) 2007-06-21
AR081991A2 (es) 2012-10-31
CN101260114B (zh) 2012-11-28
AU2004287601B8 (en) 2009-03-05
DE602004006367T2 (de) 2007-09-06
CL2004000498A1 (es) 2005-03-11
JP2014177500A (ja) 2014-09-25
CN101260115B (zh) 2011-11-23
HRP20040265A2 (en) 2004-12-31
CN101260114A (zh) 2008-09-10
US7915275B2 (en) 2011-03-29
AU2004287601B2 (en) 2009-02-26
JP2005139161A (ja) 2005-06-02
CO5560083A1 (es) 2005-09-30
US8404704B2 (en) 2013-03-26
PT1557421E (pt) 2007-07-31
DK1557421T3 (da) 2007-09-17
RS20060168A (en) 2008-09-29
IL160798A0 (en) 2004-08-31
DK1676847T3 (da) 2009-05-11
BRPI0407149A (pt) 2006-02-07
ATE421966T1 (de) 2009-02-15
MD3653F2 (en) 2008-07-31
CY1108964T1 (el) 2014-07-02
ME00424B (me) 2011-10-10
EP1676848A1 (en) 2006-07-05
CN1886408B (zh) 2010-06-09
EP1676848B1 (en) 2009-01-28
IL174271A0 (en) 2006-08-01
MD20060080A (en) 2006-11-30
ATE421965T1 (de) 2009-02-15
WO2005044823A2 (en) 2005-05-19
KR100855084B1 (ko) 2008-08-29
RS20150292A1 (en) 2015-10-30
TNSN04044A1 (en) 2006-06-01
RS20150291A1 (en) 2015-10-30
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
SI1676847T1 (sl) 2009-06-30
TWI285107B (en) 2007-08-11
JP2011057698A (ja) 2011-03-24
EP1557421A1 (en) 2005-07-27
IL174271A (en) 2010-12-30
ITMI20032144A1 (it) 2005-05-08
CY1108909T1 (el) 2014-07-02
EP1676847A1 (en) 2006-07-05
US7045620B2 (en) 2006-05-16
HK1073657A1 (en) 2005-10-14
TW200515913A (en) 2005-05-16
MXPA04002353A (es) 2005-05-11
ES2244364T1 (es) 2005-12-16
HK1092150A1 (en) 2007-02-02
ATE361927T1 (de) 2007-06-15
KR20070113327A (ko) 2007-11-28
JP2007509904A (ja) 2007-04-19
US20080132530A1 (en) 2008-06-05
DE602004006367C5 (de) 2019-04-04
CY1108017T1 (el) 2013-09-04
YU24804A (sh) 2006-08-17
US20050272754A1 (en) 2005-12-08
JP5199576B2 (ja) 2013-05-15
US20120059023A1 (en) 2012-03-08
RS54568B1 (en) 2016-06-30
CA2538546C (en) 2011-04-19
EP1676847B1 (en) 2009-01-28
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
KR100883216B1 (ko) 2009-02-13
ES2244364T3 (es) 2007-12-01
PT1676847E (pt) 2009-04-09

Similar Documents

Publication Publication Date Title
BRPI0407149A8 (pt) formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais
BRPI0608073A8 (pt) Formas polimorfas de rifaximina, processos para sua produção e uso das mesmas em composições medicinais
AR129907A2 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO, COMPOSICIÓN FARMACÉUTICA, PROCESO PARA LA PREPARACIÓN Y USOS
ES2505615T3 (es) Proceso para fabricar zeolita de tipo MWW de titanio
BRPI0508830A (pt) derivados de benzeno substituìdos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
AR029011A1 (es) Tiazoles e imidazo[4,5-b]piridinas, un proceso para su produccion, una composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
BR0210071A (pt) Composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, método para produzir um efeito inibitório de ciclo celular (anti-proliferação celular) em um animal de sangue quente
CR8975A (es) Proceso para la produccion de derivados de amina opticamente activos
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
AR037654A1 (es) Base libre de clindamicina sustancialmente cristalina, sustancia droga, composicion farmaceutica y su uso en la fabricacion de un medicamento y proceso para preparar dicha base libre cristalina de clindamicina
BRPI0409464A (pt) cadinho para um dispositivo para produzir um bloco de material cristalino e processo para sua produção
HRP20220234T1 (hr) Kristalni oblici
AR024226A1 (es) Vancorresmicina, un proceso para su produccion, un cultivo de microorganismos para su preparacion, composicion farmaceutica que la contiene
BRPI0509028A (pt) processo para produção de derivados de c-glicosìdeo de flavona
ES2237354T1 (es) Lansoprazol estable que contiene mas de 500 ppm., hasta aproximadamente 3000 ppm. de agua y mas de 200 ppm. hasta aproximadamente 5000 ppm. de alcohol.
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
BR0010637A (pt) Composto, processo para produzir um composto, composição farmacêutica ou veterinária, inibidor de metaloproteinase, e, medicamento profilático e/ou terapêutico para doenças e/ou distúrbios associados com a degradação de tecido
NO20080940L (no) Ikke-steroide forbindelser anvendbare som glukokortikoide reseptor modulatorer
TH2101003549A (th) รูปแบบผลึกของสารยับยั้ง par4
AR034095A1 (es) Derivados di-ceto aromaticos, un proceso para su preparacion, una composicion farmaceutica y su uso para la preparacion de un medicamento
AR047061A1 (es) Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida
CU23698B7 (es) Procedimiento de preparación de la forma cristalina delta d del clorhidrato de ivabradina y las composiciones farmacéuticas que las contienen
CN108558947A (zh) 一种一锅法制备磷霉素钠的方法
TH66581A (th) วิธีการทำให้สาร 1, 1-บิส(4'-ไฮดรอกซี-3'-เมธิลเฟนิล) ไซโคลเฮกเซนบริสุทธิ์ และวิธีการผลิตสารโพลีคาร์บอร์เนตจากการสารดังกล่าว
UY24614A1 (es) Procedimiento para preparar formas de dosificacion de azitromicina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL